This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SafeCode Drug Technologies Receives Investment From Biomedix Ltd.

JERUSALEM, Jan. 6, 2013 /PRNewswire/ --  SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of a voice recognition drug administration safety application announced today that Israeli's Biomedix Ltd., (TASE: BMDX), a leading Medical Device/Biotech incubator has agreed to fund and purchase SAFC shares at 0.15 cents per share. Biomedix currently holds $200,000 USD worth of SafeCode Drug Technologies shares on its books.

Biomedix is an Israel-based, publicly-traded (TASE) Life Science focused (Israeli Medical Device & Biotech companies) investment management company. Key facts about Biomedix include:

  • Biomedix Group: Biomedix controls two of Israel's largest incubators: (ATI and Meytav), and a late-stage investment arm (SpearHead)
  • Focus on very early stage projects as well as managing later stage/mature companies
  • Attractive portfolio, high growth opportunities: OVER 50 PORTFOLIO COMPANIES ACROSS ALL CLINICAL & THERAPEUTIC FIELDS
  • Proven track record of deals & collaborations with leading global partners
  • Attractive deal flow pipeline
  • More information on Biomedix Ltd. can be found at http://www.biomedixincubator.com

Concurrently, SAFC has previously announced that the share Buyback Program, which was authorized by the Board Of Directors, will commence during the month of January 2013 and is expected to last approximately 1-3 months. The shares will be returned to the Treasury of the Company to be used for further issuances for future acquisitions of companies or technology applications in the medical industry. Funding for the acquisition of the shares will be subject to financing from third parties.

Under the program approved by the BOD, SafeCode Drug Technologies Corp is authorized to repurchase up to 1 million of its outstanding shares of common stock at a price up to $0.20 per share on the open market.

"SafeCode Drug Technologies Corp continues to progress its efforts to bring further added value to its shareholders," said Joel Klopfer, CEO of SafeCode Drug Technologies Corp. "The repurchase of shares and funding commitment from Biomedix will be used to enable us to acquire additional technologies that augment our existing commercial technology and/or additional drug safety applications in the medical industry, and we will be updating our shareholders in the forthcoming weeks of new and exciting news in regards to further acquisitions."

About SafeCode Drug Technologies

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs